Screening for Hereditary Hemochromatosis in Newly Referred Diabetes Mellitus

Michael Lockhart, Muhammad Ridhwaan Salehmohamed, Dileep Kumar, Anne Graham Cummiskey, Keat Cheah Seong, Seamus Sreenan, John McDermott
{"title":"Screening for Hereditary Hemochromatosis in Newly Referred Diabetes Mellitus","authors":"Michael Lockhart,&nbsp;Muhammad Ridhwaan Salehmohamed,&nbsp;Dileep Kumar,&nbsp;Anne Graham Cummiskey,&nbsp;Keat Cheah Seong,&nbsp;Seamus Sreenan,&nbsp;John McDermott","doi":"10.1016/j.ajmo.2023.100046","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>Hereditary hemochromatosis (HH) is the most common inherited disease in European populations. It is particularly common in people of Irish heritage, approximately 2% of whom will be at risk of iron overload as a result of human homoeostatic iron regulator protein (<em>HFE</em>) gene mutations. We aimed to evaluate the utility of screening for HH in newly referred patients with DM of Irish heritage in a prospective study.</p></div><div><h3>Methods</h3><p>Of 575 patients newly referred between March 2018 and March 2021, 556 attended for blood testing, to include fasting transferrin saturations, prior to their first clinic visit. Patients with elevated transferrin saturations were further screened for hereditary hemochromatosis (HH) with <em>HFE</em> gene analysis.</p></div><div><h3>Results</h3><p>Transferrin saturations were elevated in 13 of 556 patients (2.3%), 3 of whom had a preexisting diagnosis of HH. Of the remaining 10 patients, 7 had <em>HFE</em> gene mutations suggestive of HH (2 C282Y homozygous, 3 C282Y/H63D compound heterozygous, and 2 H63D homozygous), 1 was a HH carrier (C282Y heterozygous), and 2 had normal genetics.</p></div><div><h3>Conclusions</h3><p>The prevalence of HH of 1.8% in this screened DM population is lower than the reported incidence of HH in the Irish population, suggesting a limited utility of routine screening for HH in newly referred patients with DM.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of medicine open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266703642300016X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

Hereditary hemochromatosis (HH) is the most common inherited disease in European populations. It is particularly common in people of Irish heritage, approximately 2% of whom will be at risk of iron overload as a result of human homoeostatic iron regulator protein (HFE) gene mutations. We aimed to evaluate the utility of screening for HH in newly referred patients with DM of Irish heritage in a prospective study.

Methods

Of 575 patients newly referred between March 2018 and March 2021, 556 attended for blood testing, to include fasting transferrin saturations, prior to their first clinic visit. Patients with elevated transferrin saturations were further screened for hereditary hemochromatosis (HH) with HFE gene analysis.

Results

Transferrin saturations were elevated in 13 of 556 patients (2.3%), 3 of whom had a preexisting diagnosis of HH. Of the remaining 10 patients, 7 had HFE gene mutations suggestive of HH (2 C282Y homozygous, 3 C282Y/H63D compound heterozygous, and 2 H63D homozygous), 1 was a HH carrier (C282Y heterozygous), and 2 had normal genetics.

Conclusions

The prevalence of HH of 1.8% in this screened DM population is lower than the reported incidence of HH in the Irish population, suggesting a limited utility of routine screening for HH in newly referred patients with DM.

新发糖尿病遗传性血色素沉着症的筛查
遗传性血色素沉着病(HH)是欧洲人群中最常见的遗传性疾病。它在爱尔兰血统的人中尤其常见,其中约2%的人将因人类等位铁调节蛋白(HFE)基因突变而面临铁过载的风险。在一项前瞻性研究中,我们旨在评估新转诊的爱尔兰裔糖尿病患者进行HH筛查的效用。方法在2018年3月至2021年3月期间新转诊的575名患者中,556人在首次就诊前接受了血液检测,包括空腹转铁蛋白饱和度。用HFE基因分析进一步筛选转铁蛋白饱和度升高的患者是否患有遗传性血色素沉着症(HH)。结果556例患者中有13例(2.3%)转铁蛋白饱和度升高,其中3例已有HH诊断。在其余10名患者中,7名患者的HFE基因突变提示HH(2名C282Y纯合子,3名C282Y/H63D复合杂合子,2名H63D纯合子),1名患者为HH携带者(C282Y杂合子),2名患者遗传正常。结论在该筛查的糖尿病人群中,HH的患病率为1.8%,低于爱尔兰人群中报告的HH发病率,这表明常规筛查在新转诊的糖尿病患者中的作用有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of medicine open
American journal of medicine open Medicine and Dentistry (General)
自引率
0.00%
发文量
0
审稿时长
47 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信